Uni Eropa - Hungaria - EMA (European Medicines Agency)

gilead sciences international ltd - elvitegravir - hiv fertőzések - vírusellenes szerek szisztémás alkalmazásra - vitekta adják a ritonavir növelte proteáz-gátló és más antiretroviális hatóanyagokkal szemben, javallott a kezelés a humán immundeficiencia vírus 1 (hiv-1) fertőzés a felnőttek, akik fertőzött hiv-1 ismert mutációk nélkül ellenáll a elvitegravir kapcsolódó.

Uni Eropa - Hungaria - EMA (European Medicines Agency)

roche registration ltd. - daklizumab - graft rejection; kidney transplantation - immunszuppresszánsok - zenapax javallott a profilaktikus a de novo allogén vese-transzplantáció akut szervi elutasítását, és használható együtt egy immunszupresszív kezelés, beleértve a ciklosporin és kortikoszteroidok a betegek, akik a nem magasan immunizált.

Uni Eropa - Hungaria - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - regdanvimab - covid-19 virus infection - immunrendszer sera, immunglobulinok, - regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (covid-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Uni Eropa - Hungaria - EMA (European Medicines Agency)

orphelia pharma sas - vigabatrin - spasms, infantile; epilepsies, partial - antiepileptikumok, - kigabeq jelzi a csecsemők, gyermekek 1 hónap kevesebb, mint 7 éves korig:kezelése monoterápiában a csecsemőkori görcsök (west szindróma). kezelés kombinálva más epilepszia elleni gyógyszerek a betegek ellenálló részleges epilepszia (fokális kezdeti rohamok), vagy anélkül másodlagos általánosítás, hogy a hely, ahol minden más, megfelelő gyógyszer kombinációk bizonyult, nem megfelelő vagy nem tolerálható.

Uni Eropa - Hungaria - EMA (European Medicines Agency)

biogen netherlands b.v. - diroximel fumarate (biib098) - a sclerosis multiplex, a relapszáló-remittáló - immunszuppresszánsok - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).

Uni Eropa - Hungaria - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - daganatellenes szerek - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. további információ az emberi epidermális növekedési faktor receptor 2 (her2) állapotáról, kérjük, olvassa el az 5. pontot. vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. a her2 állapotra vonatkozó további információkért lásd az 5. pontot. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Uni Eropa - Hungaria - EMA (European Medicines Agency)

baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - daganatellenes szerek - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.

Hungaria - Hungaria - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

bausch health ireland ltd. - finasteride -